Previous 10 | Next 10 |
"The most pathetic person in the world is someone who has sight, but has no vision ." - Helen Keller Equities continued to move ahead this week. Investors seem more and more confident that the massive and unprecedented stimulus provided by both Congress and the Federal Reserve will make t...
HOUSTON , May 29, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indication...
HOUSTON , May 13, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, t...
Genfit SA (NASDAQ: GNFT ) -67% after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...
Marker Therapeutics, Inc. (MRKR) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Tony Kim - Chief Financial Officer Peter Hoang - President and Chief Executive Officer Mythili Koneru - Chief Medical Officer Conference Call Participants Matt Bie...
Marker Therapeutics (NASDAQ: MRKR ): Q1 GAAP EPS of -$0.14 misses by $0.03 . More news on: Marker Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON , May 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications...
HOUSTON , May 4, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today a...
Moderna Boosts Production with Lonza Deal Moderna Therapeutics ( MRNA ) announced its new collaboration with Lonza for boosting its production capacity for mRNA 1273. The company had recently struck a deal with the federal government to focus on developing COVID 19 vaccine candidate. ...
Gainers: ThermoGenesis (NASDAQ: THMO ) +82% . More news on: ThermoGenesis Holdings, Inc., Summer Infant, Inc., Midatech Pharma plc, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...